Cue Biopharma
CUE
64 hedge funds and large institutions have $28.7M invested in Cue Biopharma in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 30 reducing their positions, and 15 closing their positions.
107% more call options, than puts
Call options by funds: $87K | Put options by funds: $42K
6.5% less ownership
Funds ownership: 42.67% → 36.17% (-6.5%)
15% less funds holding
Funds holding: 75 → 64 (-11)
57% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 30
67% less capital inflows, than outflows
Capital inflows: $1.82M | Capital outflows: $5.47M
73% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sanders Morris Harris
Houston,
Texas
|
+$321K |
| 2 |
Voss Capital
Houston,
Texas
|
+$287K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$250K |
| 4 |
GSA Capital Partners
London,
United Kingdom
|
+$248K |
| 5 |
Annandale Capital
Dallas,
Texas
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$615K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$585K |
| 3 |
Morgan Stanley
New York
|
-$517K |
| 4 |
Millennium Management
New York
|
-$464K |
| 5 |
Renaissance Technologies
New York
|
-$440K |
CUE Hedge Fund Activity: Q3 2022 in Review
64 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2022, worth a combined $28.7M — down 18% from $35M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CUE and 4 opened new positions — a net loss of 11 holders — while 30 trimmed existing stakes and 13 added.
The largest buyer was Sanders Morris Harris, adding an estimated $321K. The largest seller was Dimensional Fund Advisors, cutting an estimated $615K.
- 64 institutional investors held Cue Biopharma (CUE) as of Q3 2022, down from 75 in Q2 2022.
- Funds reported $28.7M of Cue Biopharma stock for Q3 2022, down 18% quarter-over-quarter.
- 4 funds opened new Cue Biopharma positions in Q3 2022 and 15 closed out, a net change of -11 holders.
- The largest Cue Biopharma buyer in Q3 2022 was Sanders Morris Harris, an estimated $321K added.
- The largest Cue Biopharma seller in Q3 2022 was Dimensional Fund Advisors, an estimated $615K sold.
Based on aggregated 13F filings for Q3 2022.